medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Number 2

<< Back Next >>

Ann Hepatol 2012; 11 (2)

Serum N-glycomic markers in combination with panels improves the diagnosis of chronic hepatitis B

Ying Q, Chun-Fang G, Kun Z, Yun-Peng Z, Ming-Yi X, Lun-Gen L

Language: English
References: 36
Page: 202-212
PDF size: 376.33 Kb.


ABSTRACT

Aim. The present study aimed to evaluate the changes in the serum N-glycome profiles in chronic hepatitis B (CHB) patients and to assess the role of N-glycome-derived markers in the noninvasive diagnosis of liver fibrosis. Materials and Methods. After liver biopsy for pathological grading and staging, 128 CHB patients underwent serum N-glycomic analysis using DNA sequencer-assisted fluorophore-assisted carbohydrate electrophoresis (DSA-FACE) and sensitive markers were screened. Results. Peaks 1, 2, 8 and 10 in the N-glycome profiles could, to some extents, distinguish liver fibrosis at different stages. In addition, the N-glycome-derived marker log(peak2/peak8) possessed the highest diagnostic accuracy. The areas under the receiver operating characteristic (AUROCs) curves of the log(peak2/peak8) were 0.675, 0.736 and 0.754 in the diagnosis of significant fibrosis, advanced fibrosis and early cirrhosis, respectively. In combination with some marker panels (SLFG, S index, Fibrometer, Hui, Forns, APRI and Hepascore), it showed the best diagnostic potency in distinguishing significant fibrosis (SLFG + log[peak2/peak8], AUROC = 0.813) from advanced fibrosis (SLFG + log[peak2/peak8], AUROC = 0.899) and a better diagnostic potency in the identification of early cirrhosis (S index + log[peak2/peak8], AUROC = 0.903, lower than Hui model [AUROC = 0.927]) in the validation cohort. Conclusions. N-glycomic changes are present in the serum of CHB patients with liver fibrosis, and N-glycan profiling is a noninvasive and effective tool to assess the liver fibrosis, especially in combination with serum marker panels.


REFERENCES

  1. Chan HL, Jia J. Chronic hepatitis B in Asia-new insights from the past decade. J Gastroenterol Hepatol 2011; 26(Suppl.): 131-7.

  2. Lledó JL, Fernández C, Gutiérrez ML, Ocaña S. Management of occult hepatitis B virus infection: An update for the clinician. World J Gastroenterol 2011; 17: 1563-8.

  3. Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett 2009; 286: 52-9.

  4. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500.

  5. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T, MULTIVIRC Group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-75.

  6. Forns X, Ampurdanès S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, Bruguera M, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92.

  7. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.

  8. Adams LA, Bulsara M, Rossi E, Deboer B, Speers D, George J, Kench J, et al. Hepascore: An accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51: 1867-73.

  9. Zeng MD, Lu LG, Mao YM, Qiu DK, Li JQ, Wan MB, Chen CW, et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology 2005; 42: 1437-45.

  10. Hui AY, Chan HL, Wong VW, Liew CT, Chim AM, Chan FK, Sung JJ. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol 2005; 100: 616-23.

  11. Zhou K, Gao CF, Zhao YP, Liu HL, Zheng RD, Xian JC, Xu HT, et al. Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B. J Gastroenterol Hepatol 2010; 25: 1569-77.

  12. Callewaert N, Geysens S, Molemans P, Contreras R. Ultrasensitive profiling and sequencing of N-linked oligosaccharides using standard DNA-sequencing equipment. Glycobiology 2001; 11: 275-81.

  13. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004; 10: 429-34.

  14. Liu XE, Desmyter L, Gao CF, Laroy W, Dewaele S, Vanhooren V, Wang L, et al. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology 2007; 46: 1426-35.

  15. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-4.

  16. Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006; 12: 3682-94.

  17. Giustina G, Fattovich G, De Paoli M, Guido M, Favarato S, Rugge M, Alberti A, et al. Serum procollagen type III peptide in chronic hepatitis B. Relationship to disease activity and response to interferon-alpha therapy. Int J Clin Lab Res 1996; 26: 33-6.

  18. Murawaki Y, Ikuta Y, Koda M, Kawasaki H. Serum type-III procollagen peptide, type-IV collagen 7s domain, central triple-helix of type-IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: relationship to liver histology. Hepatology 1994; 20: 780-7.

  19. Kaneda H, Hashimoto E, Yatsuji S, Tokushige K, Shiratori K. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2006; 21: 1459-65.

  20. Parsian H, Nouri M, Somi MH, Rahimipour A, Qujeq D, Fard MK, Agcheli K, et al. Relationship between serum hyaluronic acid level and stage of liver fibrosis in patients with chronic hepatitis. Biochemia Medica 2009; 19: 154-65.

  21. Smith AD, Timms PM, Oien KA, Maxwell PR, Macsween RNM, Danesh BJ. Tissue inhibitor of metalloproteinases-1, procollagen III peptide and laminin as non invasive markers of liver fibrosis. Gastroenterology 1998; 114: A1344.

  22. Boeker KHW, Michels D, Haberkorn CI, Bahr MJ, Manns MP, Lichtinghagen R. Circulating levels of TIMP-1, MMP-2, and hyaluronic acid as markers of fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32: 549A.

  23. Walsh KM, Timms P, Campbell S, MacSween RN, Morris AJ. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci 1999; 44: 624-30.

  24. Calès P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konaté A, Gallois Y, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42: 1373-81.

  25. Mahal LK. Glycomics: towards bioinformatic approaches to understanding glycosylation. Anticancer Agents Med Chem 2008; 8: 37-51.

  26. Ratner DM, Adams EW, Disney MD, Seeberger PH. Tools for glycomics: mapping interactions of carbohydrates in biological systems. Chembiochem 2004; 5: 1375-83.

  27. Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell 2006; 126: 855-67.

  28. An HJ, Kronewitter SR, de Leoz ML, Lebrilla CB. Glycomics and disease markers. Curr Opin Chem Biol 2009; 13: 601-7.

  29. Vanderschaeghe D, Laroy W, Sablon E, Halfon P, Van Hecke A, Delanghe J, Callewaert N. GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer- based serum protein glycomics. Mol Cell Proteomics 2009; 8: 986-94.

  30. Chen C, Schmilovtz-Weiss H, Liu XE, Pappo O, Halpern M, Sulkes J, Braun M, et al. Serum protein N-glycans profiling for the discovery of potential biomarkers for nonalcoholic steatohepatitis. J Proteome Res 2009; 8: 463-70.

  31. McFarlane BM, McSorley CG, Vergani D, McFarlane IG, Williams R. Serum autoantibodies reacting with the hepatic asialoglycoprotein receptor protein (hepatic lectin) in acute and chronic liver disorders. J Hepatol 1986; 3: 196-205.

  32. Lee SJ, Evers S, Roeder D, Parlow AF, Risteli J, Risteli L, Lee YC, et al. Mannose receptor-mediated regulation of serum glycoprotein homeostasis. Science 2002; 295: 1898-901.

  33. Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem 1982; 51: 531-54.

  34. Fang M, Dewaele S, Zhao YP, Stärkel P, Vanhooren V, Chen YM, Ji X, et al. Serum N-glycome biomarker for monitoring development of DENA-induced hepatocellular carcinoma in rat. Mol Cancer 2010; 9: 215.

  35. Gui HL, Gao CF, Wang H, Liu XE, Xie Q, Dewaele S, Wang L, et al. Altered serum N-glycomics in chronic hepatitis B patients. Liver Int 2010; 30: 259-67.

  36. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.




2020     |     www.medigraphic.com